ClinicalTrials.gg
RecruitingNCT07683325Updated Oct 29, 2026

NOV-ERA - A Clinical Trial to Assess the Efficacy and Safety of Ontunisertib Compared to Placebo in Patients With Fibrostenosing Crohn's Disease

A Phase 2 interventional study of Ontunisertib and Ontunisertib in Fibrostenotic Crohn's Disease, sponsored by Agomab Spain S.L.U.. Recruiting at 11 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Agomab Spain S.L.U. (part of Agomab Therapeutics NV) · Phase 2, Interventional, and Treatment

Updated Oct 29, 2026First sites in Serbia and United Kingdom9 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
320
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 660 studies in Crohn Disease with a site in United States — 122 open to participants now, 163 under way, 35 of them phase 3. Crohn Disease · United States.

Planned enrollment
81st of 528
320 · median 60
Started
2026
with 34 others
Phase 2
141 of 660
23 open now
Primary completion
2028-12
later than 119 of 162 live
Registered
653rd of 660
by date

Among the 660 studies in Crohn Disease with a site in United States, this one is the 81st largest by planned enrollment of the 528 interventional ones that give a count, is one of 35 that started in 2026, is one of 141 in phase 2, reaches primary completion later than 119 of the 162 other live ones, and was the 653rd registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

122 of the 660 studies in Crohn Disease with a site in United States are open now. Recruiting first, the newest first:

116 more — sign in →

All 122 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 660 studies in Crohn Disease with a site in United States, or all of them as a file.
02

Study summary

Many patients with Crohn's disease (CD) develop fibrotic narrowing (strictures) in their bowel, causing obstructive symptoms such as abdominal pain, cramping, or vomiting after meals. Because of these symptoms, patients often require bowel resection surgery. The objective of this clinical trial is to evaluate the efficacy, safety, and dose-response relationship of ontunisertib in participants with CD and symptomatic strictures, and contribute to the validation of novel endpoints to assess potential treatment benefit in patients with fibrostenosing Crohn's disease (FSCD).

The participants will be in the trial for a duration of up to 60 weeks, consisting of a 6-week screening period (with 2 screening visits), a 52-week treatment period, and a 2-week follow-up period. The visit frequency in the treatment period will be every 6 to 8 weeks.

Read the detailed description

This is a randomized, double-blind, placebo-controlled, dose-ranging, multicenter Phase 2b trial to assess the efficacy and safety of ontunisertib in participants diagnosed with FSCD. The trial population will include adults 18 years of age and older with symptomatic FSCD based on clinical, endoscopic, and radiological criteria.

This trial consists of 3 periods (a screening period, a placebo-controlled, double-blind treatment period, and safety follow-up). After signing informed consent, eligibility will be assessed during a 6-week screening period. The presence of qualifying intestinal strictures will be assessed by ileocolonoscopy and magnetic resonance enterography (MRE). The presence of obstructive symptoms will also be evaluated.

Eligible participants will be randomized 1:1:1:1 to receive AGMB-129 (Ontunisertib) high dose, medium dose, low dose or placebo for 52 weeks.

During Screening and Weeks 24 and 52 visits, participants will undergo ileocolonoscopy with biopsy collection for exploring pharmacodynamics. Participants will have blood sample collection at Weeks 6, 12, 18, 24, 30, 36, 44 and 52 to assess safety, pharmacokinetics, and pharmacodynamics.

Throughout the study, participants will undergo routine safety assessments at study visits, which will include physical examination, vital signs, clinical laboratory assessment, electrocardiogram (ECG), and recording of AEs.

03

Conditions studied

  • Fibrostenotic Crohn's Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of ileal or ileocolonic CD based on clinical and endoscopic or radiological evidence established at least 12 weeks prior to signing the ICF.
  • Presence of at least 1 endoscopically non-passable ileal stricture.
  • Present stricture(s) can be naïve or anastomotic, and will be confirmed by centrally read MRE.
  • Presence of (sub)obstructive symptoms AND/OR dietary restrictions like limiting the amount or type of food, and/or food processing methods.
  • Participants should be on stable anti-inflammatory background therapy for CD and agree to maintain stable background therapy for the duration of the trial.
  • Participants should have a ≥18 kg/m2 and \<35 kg/m2.
  • Not expected in the investigator's opinion to require hospitalization, endoscopic balloon dilation, surgical resection, or optimized anti-inflammatory therapy during the first 4 weeks of the trial.

Exclusion criteria

Exclusion Criteria:

  • History or current diagnosis of ulcerative colitis, indeterminate colitis, ischemic colitis, nonsteroidal anti-inflammatory drug-induced colitis, idiopathic colitis (i.e., colitis not consistent with CD), radiation colitis, microscopic colitis, colonic mucosal dysplasia, untreated bile acid malabsorption, or infectious colitis.
  • CD-related complications:

    1. Short bowel syndrome (\<200 cm small bowel remaining).
    2. Ileostomy (diverting or end), colostomy, small bowel stoma, or ileoanal pouch.
    3. Internal fistulae and sinus tracts deriving from the area of stenosis. Participants with perianal fistulae could be included if not septic.
    4. Anal and perianal stricture.
    5. Suspected or diagnosed active intra-abdominal or perianal abscess that has not been appropriately treated and abscess in relation to the stricture.
    6. Toxic megacolon.
    7. Blind-ending sinus could be included.
  • Endoscopic balloon dilation or surgical treatment of the index small bowel stricture within the last 6 months prior to screening.
  • Current or history of valvulopathy, or moderate or severe heart valve function defect, including moderate or severe valve stenosis or regurgitation OR \<50% as assessed locally through echocardiography.
  • Any other severe acute or chronic medical condition, psychiatric disorder, laboratory abnormality, or systemic or opportunistic infection that may increase the risk associated with trial participation or trial treatment administration, or may interfere with the interpretation of trial results, as determined by the investigator.
  • abnormal vital signs, physical examination, or abnormalities at 12-lead at screening or baseline.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
320 participants (estimated)

Study arms

  • Experimental
    Ontunisertib High

    Ontunisertib high dose

    Drug: Ontunisertib

  • Experimental
    Ontunisertib Medium

    Ontunisertib medium dose

    Drug: Ontunisertib

  • Experimental
    Ontunisertib Low

    Ontunisertib low dose

    Drug: Ontunisertib

  • Experimental
    Placebo

    Matching placebo

    Drug: Placebo

Interventions

  • Oral capsule

    Also known as: AGMB-129

  • Oral capsule

    Also known as: AGMB-129

  • Oral capsule

    Also known as: AGMB-129

  • DrugPlacebo

    Matching oral capsule

06

What researchers measure

Primary outcomes

  1. Proportion of participants achieving endoscopic passability of the ileal index stricture

    To evaluate the efficacy and dose-response relationship of multiple doses of ontunisertib

    Time frame: At week 24

Secondary outcomes

  1. Proportion of participants achieving endoscopic passability of the ileal index stricture

    To evaluate the efficacy of ontunisertib in participants with FSCD, compared to placebo

    Time frame: At week 52

  2. Change in reliable MRE imaging features (stricture length, bowel wall thickness, prestenotic dilatation diameter) of the index stricture

    To evaluate the efficacy of ontunisertib in participants with FSCD, compared to placebo

    Time frame: At week 52 compared to baseline (week 1)

  3. Change in total SES-CD (range, 0-56 points) (Reference: https://www.giejournal.org/article/S0016-5107(04)01878-4/abstract)

    To evaluate the efficacy of ontunisertib in participants with FSCD, compared to placebo

    Time frame: At week 52 compared to baseline

  4. Proportion of participants with an endoscopic response (≥50% decrease in total SES-CD) and remission (SES-CD ≤4 with no item >1)

    To evaluate the efficacy of ontunisertib in participants with FSCD, compared to placebo

    Time frame: At week 52 compared to baseline

  5. Change in S-PRO severity score

    To evaluate the efficacy of ontunisertib in participants with FSCD, compared to placebo

    Time frame: At week 52 compared to baseline

  6. Time to an FSCD- related event

    To evaluate the efficacy of ontunisertib in participants with FSCD, compared to placebo

    Time frame: From baseline to week 52

  7. Number of participants with adverse events (AEs)

    To evaluate the safety and tolerability of ontunisertib in participants with FSCD, compared to placebo

    Time frame: From baseline to week 52

  8. Number of participants with abnormal clinical laboratory tests

    To evaluate the safety and tolerability of ontunisertib in participants with FSCD, compared to placebo

    Time frame: From baseline to week 52

  9. Number of participants with abnormal ECG parameters

    To evaluate the safety and tolerability of ontunisertib in participants with FSCD, compared to placebo

    Time frame: From baseline to week 52

  10. Number of participants with abnormal vital signs

    To evaluate the safety and tolerability of ontunisertib in participants with FSCD, compared to placebo

    Time frame: From baseline to week 52

  11. Number of participants with abnormal physical examinations

    To evaluate the safety and tolerability of ontunisertib in participants with FSCD, compared to placebo

    Time frame: From baseline to week 52

  12. Plasma level concentration of ontunisertib and metabolites

    To evaluate the PK (AUC) of ontunisertib in participants with FSCD

    Time frame: From baseline to week 52

07

Study locations

11 of 11 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

4 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Dec 2028, 26 months later.

Of 56 industry-sponsored phase 2 interventional studies under Crohn Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's planned 26 months is below that.

Counting every sponsor, half of 83 studies reached it within 34 months; a quarter within 23 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2026
First posted
Jul 6, 2026
StartEst.
Oct 30, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Jun 30, 2029
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
9 sites added — first sites in Serbia and United Kingdom
Show 9 added (5 United States, 3 Serbia, 1 United Kingdom)
  • Amel Med LLC · Georgetown, United States
  • University Gastroenterology · Providence, United States
  • Albany Gastroenterology Consultants · Albany, United States
  • GI Alliance · Sun City, United States
  • GI Alliance · Cedar Park, United States
  • Clinical Hospital Center "Dr. Dragisa Misovic-Dedinje" · Belgrade, Serbia
  • Clinical Hospital Center Bezanijska Kosa · Belgrade, Serbia
  • Clinical Hospital Center Zvezdara (CHCZ) · Belgrade, Serbia
  • Royal London Hospital · London, United Kingdom
across 4 updates, Sep 28, 2026 – Oct 29, 2026
Show all 4 updates
  1. Oct 29, 2026
    6 sites added — first sites in Serbia and United Kingdom
    Show 6 added (3 Serbia, 2 United States, 1 United Kingdom)
    • GI Alliance · Sun City, United States
    • GI Alliance · Cedar Park, United States
    • Clinical Hospital Center "Dr. Dragisa Misovic-Dedinje" · Belgrade, Serbia
    • Clinical Hospital Center Bezanijska Kosa · Belgrade, Serbia
    • Clinical Hospital Center Zvezdara (CHCZ) · Belgrade, Serbia
    • Royal London Hospital · London, United Kingdom
  2. Oct 19, 2026
    1 site added
    Show site
    • Albany Gastroenterology Consultants · Albany, United States
  3. Oct 5, 2026
    1 site added
    Show site
    • University Gastroenterology · Providence, United States
    + 1 other change: verification date
  4. Sep 28, 2026
    1 site added
    Show site
    • Amel Med LLC · Georgetown, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07683325
Responsible party
Sponsor
First posted
Jul 6, 2026
Start date
Oct 30, 2026 (estimated)
Primary completion
Dec 31, 2028 (estimated)
Completion
Jun 30, 2029 (estimated)
Last update
Oct 29, 2026

Study contacts

Agomab Clinical Operations
Contact
clinicalstudies@agomab.com
0032 3318 91 70
Silke Hüttner, MD
study director · Agomab Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ontunisertib

Start the discussion